Spyre Therapeutics, Inc.
SYRE
$75.87
$0.831.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.36% | -459.15% | 69.54% | 17.99% | 20.47% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.67% | 163.43% | -3,859.50% | -118.52% | -47.62% |
| Change in Net Operating Assets | 110.77% | -138.13% | 165.70% | -1,491.73% | -105.26% |
| Cash from Operations | -28.70% | -20.10% | 20.29% | -13.58% | -10.20% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 123.54% | -1,061.72% | -65.28% | 118,129.51% | 99.96% |
| Cash from Investing | 122.87% | -1,089.72% | -68.36% | 129,604.92% | 99.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.03% | 63,623.22% | -32.83% | 235.32% | -99.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -147.83% | 98.66% | -- | 100.00% | 71.65% |
| Cash from Financing | -96.08% | 6,837.28% | -735.16% | 484.80% | -99.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -44.95% | 224.23% | -150.54% | 181.03% | -329.39% |